Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DomaniCell is a biotechnology company specializing in the collection, processing, and cryopreservation of stem cells derived from postpartum tissues, including the placenta and umbilical cord. As a subsidiary of Celularity, the company provides a platform for individuals to bank their own biological materials for potential future use in regenerative medicine and cellular therapies. The company was founded by Dr. Robert Hariri, a pioneer in the use of placental-derived cells for therapeutic applications. DomaniCell's services are integrated into a broader ecosystem aimed at developing off-the-shelf cellular treatments for cancer, infectious diseases, and degenerative conditions. By securing high-quality cellular assets at birth, DomaniCell aims to provide a lifelong resource for personalized medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DomaniCell.